Inflammation has been recognized as a major pathophysiological contributor to the entire
spectrum of human heart failure (HF), including HF with reduced ejection fraction, HF with …

Many patients with symptoms and signs of heart failure have a left ventricular ejection
fraction≥ 50%, termed heart failure with preserved ejection fraction (HFpEF). HFpEF is a …

Overlapping pandemics of lifestyle-related diseases pose a substantial threat to
cardiovascular health. Apart from coronary artery disease, metabolic disturbances linked to …

Background: Inflammation may play a role in the pathophysiology of heart failure with
preserved ejection fraction. We examined whether circulating levels of interleukin-6 identify …

Abstract Background Interleukin (IL)-6 is a central inflammatory mediator and potential
therapeutic target in heart failure (HF). Prior studies have shown that IL-6 concentrations are …

Abstract Aims Interleukin-6 (IL-6) and interleukin-18 (IL-18), important cytokines implicated
in atherosclerosis and inflammaging, were assessed for associations with global …

Purpose Several studies have reported that colchicine attenuates cardiac inflammation and
improves cardiac function in myocardial infarction and atrial fibrillation. However, no study …

Chronic low-grade elevations of blood-borne cytokines/chemokines in older age tend to
associate with frailty in humans. This persistent inflammation is often called “inflammageing” …

Chronic systemic inflammation is associated with an increased risk of heart failure (HF). We
sought to determine the association between biomarkers of systemic inflammation …

The immune system is intimately involved in the pathophysiology of heart failure. However, it
is currently underused as a therapeutic target in the clinical setting. Moreover, the …